Targeting Tumor Vasculature Using Adeno-Associated Virus Phage Vectors Coding Tumor Necrosis Factorα

Zi Qiang Yuan, Jessica Pastoriza, Thomas Quinn, Steven K. Libutti

Research output: Chapter in Book/Report/Conference proceedingChapter

7 Scopus citations


An advantage of targeted gene therapy is the potential for effectively delivering anti-vascular and antitumor therapy directly to the site of the tumor, thus maximizing therapeutic efficacy and minimizing toxicity. The use of a vector capable of directed cell transduction can result in the sustained expression of the therapeutic agent. This chapter reviews the current status of vector strategies, targeted gene therapy with tumor-specific promoter and antibody and peptide conjugation, and outlines the challenges faced for the next-generation of gene transfer technology. Furthermore, it summarizes the results of preclinical anti-angiogenic gene therapy investigations, which utilize novel targeted tumor necrosis factorα treatment, and discusses potential clinical applications of this treatment strategy.

Original languageEnglish (US)
Title of host publicationGene Therapy of Cancer
Subtitle of host publicationTranslational Approaches from Preclinical Studies to Clinical Implementation: Third Edition
PublisherElsevier Inc.
Number of pages15
ISBN (Print)9780123942951
StatePublished - Aug 2013


  • Adeno-associated virus phage
  • Antibody conjugation
  • Nonviral vector
  • Peptide conjugation
  • Targeted anti-angiogenic gene therapy
  • Tumor necrosis factorα
  • Tumor-specific promoter
  • Viral vector

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)


Dive into the research topics of 'Targeting Tumor Vasculature Using Adeno-Associated Virus Phage Vectors Coding Tumor Necrosis Factorα'. Together they form a unique fingerprint.

Cite this